CAJ | 학술논문

目的：探讨髓源抑制细胞(MDSCs)在胃肠道恶性肿瘤患者外周血的表达及临床意义。方法收集20名健康志愿者(年龄28～50岁，平均36岁)和59名新诊断的胃肠道恶性肿瘤患者(年龄27～80岁，平均59岁)的外周血，用荧光标记的抗人Lin1、HLA DR、CD33及CD11b单克隆抗体标记肿瘤患者和健康人的外周血细胞，应用流式细胞分析术检测MDSCs (Lin-/Lo HLA DR-CD33+CD11b+)细胞的表达。结果胃肠道恶性肿瘤患者的MDSCs百分比为(3.99±1.24)％，明显高于健康人群(1.81±0.74，P<0.01)；伴肿瘤转移者(5.34±1.54)％和非转移肿瘤患者(3.71±1.46)％比较，有统计学差异(P<0.05)；胃癌患者MDSCs (3.57±1.59)％和肠癌(4.31±1.71)％相比，无统计学意义(P>0.05)；所有肿瘤患者中，同时患有高血压、糖尿病者19例，MDSCs平均(3.62±1.16)％，和一般肿瘤病人比较，无差异(P>0.05)。结论 MDSCs在胃肠道恶性肿瘤中表达增高，肿瘤继发转移者增加更明显，可用于判断病情和预后；但在不同组织来源肿瘤中的表达不具有特异性，高血压、糖尿病等基础疾病对MDSCs在影响肿瘤发生发展方面无明显影响。
목적：탐토수원억제세포(MDSCs)재위장도악성종류환자외주혈적표체급림상의의。방법수집20명건강지원자(년령28～50세，평균36세)화59명신진단적위장도악성종류환자(년령27～80세，평균59세)적외주혈，용형광표기적항인Lin1、HLA DR、CD33급CD11b단극륭항체표기종류환자화건강인적외주혈세포，응용류식세포분석술검측MDSCs (Lin-/Lo HLA DR-CD33+CD11b+)세포적표체。결과위장도악성종류환자적MDSCs백분비위(3.99±1.24)％，명현고우건강인군(1.81±0.74，P<0.01)；반종류전이자(5.34±1.54)％화비전이종류환자(3.71±1.46)％비교，유통계학차이(P<0.05)；위암환자MDSCs (3.57±1.59)％화장암(4.31±1.71)％상비，무통계학의의(P>0.05)；소유종류환자중，동시환유고혈압、당뇨병자19례，MDSCs평균(3.62±1.16)％，화일반종류병인비교，무차이(P>0.05)。결론 MDSCs재위장도악성종류중표체증고，종류계발전이자증가경명현，가용우판단병정화예후；단재불동조직래원종류중적표체불구유특이성，고혈압、당뇨병등기출질병대MDSCs재영향종류발생발전방면무명현영향。
Objective To explore the expression and clinical significance of myeloid-derived suppressor cells (MDSCs) in pe-ripheral blood in patients with gastrointestinal cancer. Methods The peripheral blood samples were Collected from 20 healthy vol-unteers (aged 28 to 50 years, mean 36 years) and 59 newly diagnosed patients (aged 27 to 80 years, mean 59 years) with gastroin-testinal cancer. The peripheral blood cells from tumor patients and healthy persons were labeled with fluorescent labeled anti-hu-man Lin1, HLA DR, CD33 and CD11b monoclonal antibody. The MDSCs(Lin-/Lo HLA DR-CD33+CD11b+) were detected with flow cytometry. Results The percentage (3.99 ±1.24%) of MDSCs in patients with gastrointestinal cancer was significantly higher than the healthy persons (1.81 ±0.74%, P<0.01); Significant difference existed between metastatic tumors (5.34 ±1.54%) and non-metastatic tumors (3.71±1.46%).There was no statistical significance(P>0.05) in MDSCs between patients with gastric cancer (3.57± 1.59%) and patients with colon cancer (4.31±1.71%). There were 19 cases among all cancer patients also suffering from high blood pressure and diabetes. The average level of MDSCs was (3.62±1.16%), and there was no difference when compared with patients of general cancer (P>0.05). Conclusion MDSCs increases in gastrointestinal malignant tumor, and more obviously in metastatic tu-mors, which can be used to determine the severity and prognosis of tumors. But it is not specific in tumors with different tissue source. High blood pressure, diabetes and other basic diseases influence tumors' development slightly in MDSCs.